Likely EU rejection of Biogen's Alzheimer's drug comes as no surprise, says dementia researcher

The negative opinion from a trend vote from the EMA's expert committee, the CHMP, was to be expected, says director of clinical trial unit at the Danish Dementia Research Center. The FDA, not the EMA, has been the outlier in common approval practices.
Photo: Nationalt Videnscenter for Demens / PR
Photo: Nationalt Videnscenter for Demens / PR
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL PEDERSEN

It is in the cards, and thus should come as no big surprise, that the pharmaceutical company Biogen is very likely to receive the European thumbs-down for its Alzheimer's drug, Aduhelm (aducanumab).

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading